Overview

Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy, safety and pharmacokinetics profile of KPS-0373 in patients with SCD
Phase:
Phase 2
Details
Lead Sponsor:
Kissei Pharmaceutical Co., Ltd.
Treatments:
Thyrotropin-Releasing Hormone